Revenio Group Corporation: Decisions by the Annual General Meeting

Report this content

Revenio Group Corporation, Stock Exchange Release, 20 March 2019 at 18.00

Decisions by the Annual General Meeting of Revenio Group Corporation on 20 March 2019

1. Financial statements, Board and Auditors

The AGM confirmed the company's financial statements for the financial year 1 January – 31 December 2018, and discharged the members of the Board of Directors and the Managing Director from liability.

The AGM decided that five members be elected to the Board of Directors and re-elected Ari Kohonen, Pekka Rönkä, Kyösti Kakkonen, Ann-Christine Sundell and Pekka Tammela as Board members. In the board meeting held after the AGM, the Board of Directors elected Pekka Rönkä as Chair of the Board.

The AGM decided that the Chairman of the Board be entitled to an annual emolument of EUR 48,000 and the other Board members to an annual emolument of EUR 24,000.

A total of 40 per cent of Board members' emoluments will be settled in the form of company shares, while 60 per cent will be comprised of a monetary payment.

The AGM further decided that an attendance allowance of EUR 500 per meeting will be paid to members of prospective committees.

The AGM re-elected Deloitte Ltd, Authorized Public Accountants, as the company's auditors, with Authorized Public Accountant (KHT) Merja Itäniemi acting as the principal auditor. The AGM decided to pay the auditors’ fees as invoiced and approved by the company.

2. Annual profit distribution, dividend distribution and capital repayment

The AGM decided to accept the Board's proposal on profit distribution, according to which the parent company’s profit for the financial period, EUR 5,430,430.59, will be added to retained earnings, and a dividend of EUR 0.28 per share will be paid. Dividends will be paid to shareholders who have been registered in the company's shareholder register, maintained by Euroclear Finland Ltd, by the dividend record date on 22 March 2018. The dividend payment date is 29 March 2019.

3. Authorizing the Board of Directors to decide to repurchase the Company's own shares

Since the Board’s proposal for a share issue without payment referred to above was approved by the AGM, the AGM authorized the Board of Directors to resolve on the acquisition of a maximum of 2,401,647 of the company’s own shares in one or more tranches using the company’s unrestricted equity. The company may buy back shares in order to develop its capital structure, finance and implement any corporate acquisitions or other transactions, implement share-based incentive plans, or otherwise transfer or cancel them.

The company may buy back shares in public trading on marketplaces whose rules and regulations allow the company to trade in its own shares. In such a case, the company buys back shares through a directed purchase, that is, in a proportion other than its shareholders’ holdings in company shares, with the consideration for the shares based on their publicly quoted market price so that the minimum price of the purchased shares equals the lowest market price quoted in public trading during the authorization period, and, similarly, their highest price equals the highest market price quoted in public trading during that period.

The authorization shall remain valid until 30 April 2020. This authorization shall supersede the buyback authorization granted at the AGM of 20 March 2018.

4. Authorizing the Board of Directors to decide on a share issue and on granting stock options and other special rights entitling to shares

The Board abandoned its proposal.

Revenio Group Corporation

Board of Directors

For further information, please contact:

CEO and President Timo Hildén, tel. +358 40 580 4774


Nasdaq Helsinki

Financial Supervisory Authority (FIN-FSA)

Main media

Revenio Group in brief

Revenio is a Finnish, globally operating health technology corporation whose worldwide success is based on strongly patented intraocular pressure measurement technology.

The Revenio Group consists of Icare Finland Oy, Revenio Research Oy and Oscare Medical Oy. The common denominators of Revenio's business operations include screening, follow-up and the global need to make cost savings through preventive health care.

Revenio seeks vigorous growth in health technology. Revenio aims to develop even more efficient and easily adopted methods for the early-stage detection of diseases with significance for public health. The focus of Revenio's screening technology is on the early detection of glaucoma, osteoporosis, skin cancer and asthma, and the monitoring of these during the treatment process.

In 2018, Revenio Group's net sales totalled EUR 30.7 million, with its net operating profit standing at 33.3%. Revenio Group Corporation is listed on Nasdaq Helsinki.